C. Le Tourneau, et al. SITC 2024 Abstract available on the SITC website – Download the abstract and the poster
Category: Myvac
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
SITC 2024
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment
ProBioGen
Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
SITC 2024
Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
A. Lalanne, et al. AACR 2024 Abstract available on the AACR website – Download the poster Poster Presentation
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
TG4050 AACR 2024
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
TG4050 AACR 2024
Transgene, Nec, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Transgene Nec and BostonGene expand collaboration
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Transgene and NEC extend their collaboration
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
Transgene and NEC present New Data on TG4050 at ASCO 2023